Preoperative neutrophil-lymphocyte ratio/platelet-lymphocyte ratio: A potential and economical marker for renal cell carcinoma
Background: Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammat...
Saved in:
| Published in | Journal of cancer research and therapeutics Vol. 18; no. 6; pp. 1635 - 1639 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Mumbai
Wolters Kluwer India Pvt. Ltd
01.10.2022
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background: Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammatory factor which is potential, noninvasive, simple, as well as economical. The preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in RCC patients have shown favorable results.
Objective: The objective was to assess the prognostic role of NLR/PLR in the advanced stage and high-grade RCC.
Subjects and Methods: This is a retrospective study. Ethical clearance was obtained from the institute ethics committee. One hundred and fifty histopathologically proven RCC cases during the period of January 2010-September 2018 were chosen from the pathology department and corresponding blood reports were obtained from the medical records department. We divided the cases based on their staging and grading. NLR/PLR values were calculated using formulas.
Statistical Analysis: Statistical analysis was done using R software. Data were expressed as mean ± standard deviation, median, and percentage. Independent t-test, Mann-Whitney test, and Chi-square test were used. P < 0.05 was considered statistically significant. The receiver operating characteristic curve (ROC) was plotted to assess the sensitivity of NLR/PLR.
Results: The elevated NLR/PLR values showed a significant relation with high-grade and advanced stage RCC. The ROC curve proved the accuracy of NLR/PLR in the advanced stage and high-grade RCC.
Limitations: A multicentric, prospective study can be planned in the future. Follow-up studies are needed to assess their prognostic role.
Conclusion: NLR/PLR values can become part of routine investigations for all RCC patients. The values may help to estimate pathological outcomes, chance of recovery, recurrence, and survival rates. |
|---|---|
| AbstractList | Background: Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammatory factor which is potential, noninvasive, simple, as well as economical. The preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in RCC patients have shown favorable results. Objective: The objective was to assess the prognostic role of NLR/PLR in the advanced stage and high-grade RCC. Subjects and Methods: This is a retrospective study. Ethical clearance was obtained from the institute ethics committee. One hundred and fifty histopathologically proven RCC cases during the period of January 2010–September 2018 were chosen from the pathology department and corresponding blood reports were obtained from the medical records department. We divided the cases based on their staging and grading. NLR/PLR values were calculated using formulas. Statistical Analysis: Statistical analysis was done using R software. Data were expressed as mean ± standard deviation, median, and percentage. Independent t-test, Mann–Whitney test, and Chi-square test were used. P < 0.05 was considered statistically significant. The receiver operating characteristic curve (ROC) was plotted to assess the sensitivity of NLR/PLR. Results: The elevated NLR/PLR values showed a significant relation with high-grade and advanced stage RCC. The ROC curve proved the accuracy of NLR/PLR in the advanced stage and high-grade RCC. Limitations: A multicentric, prospective study can be planned in the future. Follow-up studies are needed to assess their prognostic role. Conclusion: NLR/PLR values can become part of routine investigations for all RCC patients. The values may help to estimate pathological outcomes, chance of recovery, recurrence, and survival rates. Background: Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammatory factor which is potential, noninvasive, simple, as well as economical. The preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in RCC patients have shown favorable results. Objective: The objective was to assess the prognostic role of NLR/PLR in the advanced stage and high-grade RCC. Subjects and Methods: This is a retrospective study. Ethical clearance was obtained from the institute ethics committee. One hundred and fifty histopathologically proven RCC cases during the period of January 2010-September 2018 were chosen from the pathology department and corresponding blood reports were obtained from the medical records department. We divided the cases based on their staging and grading. NLR/PLR values were calculated using formulas. Statistical Analysis: Statistical analysis was done using R software. Data were expressed as mean ± standard deviation, median, and percentage. Independent t-test, Mann-Whitney test, and Chi-square test were used. P < 0.05 was considered statistically significant. The receiver operating characteristic curve (ROC) was plotted to assess the sensitivity of NLR/PLR. Results: The elevated NLR/PLR values showed a significant relation with high-grade and advanced stage RCC. The ROC curve proved the accuracy of NLR/PLR in the advanced stage and high-grade RCC. Limitations: A multicentric, prospective study can be planned in the future. Follow-up studies are needed to assess their prognostic role. Conclusion: NLR/PLR values can become part of routine investigations for all RCC patients. The values may help to estimate pathological outcomes, chance of recovery, recurrence, and survival rates. Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammatory factor which is potential, noninvasive, simple, as well as economical. The preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in RCC patients have shown favorable results.BackgroundEmerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers showed promising prognostic factors in renal cell carcinoma (RCC). We intended to evaluate the significance of one such inflammatory factor which is potential, noninvasive, simple, as well as economical. The preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in RCC patients have shown favorable results.The objective was to assess the prognostic role of NLR/PLR in the advanced stage and high-grade RCC.ObjectiveThe objective was to assess the prognostic role of NLR/PLR in the advanced stage and high-grade RCC.This is a retrospective study. Ethical clearance was obtained from the institute ethics committee. One hundred and fifty histopathologically proven RCC cases during the period of January 2010-September 2018 were chosen from the pathology department and corresponding blood reports were obtained from the medical records department. We divided the cases based on their staging and grading. NLR/PLR values were calculated using formulas.Subjects and MethodsThis is a retrospective study. Ethical clearance was obtained from the institute ethics committee. One hundred and fifty histopathologically proven RCC cases during the period of January 2010-September 2018 were chosen from the pathology department and corresponding blood reports were obtained from the medical records department. We divided the cases based on their staging and grading. NLR/PLR values were calculated using formulas.Statistical analysis was done using R software. Data were expressed as mean ± standard deviation, median, and percentage. Independent t-test, Mann-Whitney test, and Chi-square test were used. P < 0.05 was considered statistically significant. The receiver operating characteristic curve (ROC) was plotted to assess the sensitivity of NLR/PLR.Statistical AnalysisStatistical analysis was done using R software. Data were expressed as mean ± standard deviation, median, and percentage. Independent t-test, Mann-Whitney test, and Chi-square test were used. P < 0.05 was considered statistically significant. The receiver operating characteristic curve (ROC) was plotted to assess the sensitivity of NLR/PLR.The elevated NLR/PLR values showed a significant relation with high-grade and advanced stage RCC. The ROC curve proved the accuracy of NLR/PLR in the advanced stage and high-grade RCC.ResultsThe elevated NLR/PLR values showed a significant relation with high-grade and advanced stage RCC. The ROC curve proved the accuracy of NLR/PLR in the advanced stage and high-grade RCC.A multicentric, prospective study can be planned in the future. Follow-up studies are needed to assess their prognostic role.LimitationsA multicentric, prospective study can be planned in the future. Follow-up studies are needed to assess their prognostic role.NLR/PLR values can become part of routine investigations for all RCC patients. The values may help to estimate pathological outcomes, chance of recovery, recurrence, and survival rates.ConclusionNLR/PLR values can become part of routine investigations for all RCC patients. The values may help to estimate pathological outcomes, chance of recovery, recurrence, and survival rates. |
| Audience | Professional |
| Author | Kathiresan, N Chandrasekaran, Deepika Sundaram, Sandhya Padmavathi, R Maheshkumar, K |
| Author_xml | – sequence: 1 givenname: Deepika surname: Chandrasekaran fullname: Chandrasekaran, Deepika organization: Department of Physiology, Sri Ramachandra Institute of Higher Education and Research, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu – sequence: 2 givenname: Sandhya surname: Sundaram fullname: Sundaram, Sandhya organization: Department of Pathology, Sri Ramachandra Institute of Higher Education and Research, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu – sequence: 3 givenname: K surname: Maheshkumar fullname: Maheshkumar, K organization: Department of Physiology and Biochemistry, Government Yoga and Naturopathy Medical College and Hospital, Chennai, Tamil Nadu – sequence: 4 givenname: N surname: Kathiresan fullname: Kathiresan, N organization: Department of Surgical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu – sequence: 5 givenname: R surname: Padmavathi fullname: Padmavathi, R organization: Department of Physiology, Sri Ramachandra Institute of Higher Education and Research, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu |
| BookMark | eNp9kk1v1DAQhi1UJLaFO8dIXLhk64kTJ-G2WvFRVAmEytlynHHrXa8dHIfVXvjtOF0QUBZkyZZnnnc0mnnPyZnzDgl5DnRZAmWXGxXi8v36040om0IU9BFZQNs2eQmsOSML2tYsh5R6Qs7HcUNpVRdFsyDfPgb0AwYZzVfMHE4x-OHO2NwedsOdV4eI2Zz0l4OVES3GvzKvslU2-IguGmkz6foMlXd-Z1T67mTYYsi0D1lAlwIKbbpkUCYh8il5rKUd8dmP94J8fvP6Zv0uv_7w9mq9us5VyVuZS91yDR1vGQCwjoEGwK7vQWNN247TvgJdNx3VdUW5LrlineYIFCRUTSPZBXl5rDsE_2XCMYqdGedWpEM_jaKoWUt5Qzkk9MUDdOOnkFq_pxra0Krkv6hbaVEYp30MUs1Fxaou6qKty7JIVH6CukWXBm7T_rRJ4T_45Qk-nR7TOE8K-FGggh_HgFooE-eluCQ0VgAVszvE7A7xmzuSkD4QDsGkZR3-J1kfJXtvI4Zxa6c9BrHDfuv8_p86AZxV4qfN2Hf2Htkh |
| CitedBy_id | crossref_primary_10_3389_fimmu_2025_1518647 crossref_primary_10_56294_saludcyt2023232 crossref_primary_10_1007_s13304_023_01669_3 crossref_primary_10_3892_ol_2025_14977 crossref_primary_10_1002_cam4_7214 |
| Cites_doi | 10.1371/journal.pone.0125538 10.1016/S1470-2045(14)70263-3 10.1155/2019/6036979 10.1016/j.ejca.2011.03.028 10.1038/bjc.2014.180 10.3322/caac.21551 10.1590/S1677-5538.IBJU.2015.0397 10.1186/s12885-015-1304-z 10.1016/j.juro.2010.05.028 10.1016/j.imlet.2015.05.018 10.1002/ijc.31937 10.1007/s00018-017-2686-7 10.2147/ITT.S134850 10.1038/bjc.2015.241 10.1093/jnci/dju124 10.1155/2019/7309205 10.1093/annonc/mds256 10.1016/j.urolonc.2014.04.001 10.1016/j.clgc.2018.01.010 10.1016/j.clgc.2016.12.001 10.1177/1724600818817557 10.1155/2016/5634148 10.1016/j.cell.2010.01.025 10.2217/fon.09.136 10.1007/s00345-018-2286-7 10.18632/oncotarget.20147 10.1002/ijc.28536 10.1038/bjc.2013.28 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. 2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. – notice: 2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.4103/jcrt.JCRT_482_20 |
| DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1998-4138 |
| EndPage | 1639 |
| ExternalDocumentID | A727297442 10_4103_jcrt_JCRT_482_20 10.4103/jcrt.JCRT_482_20_1635_Preopera |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GroupedDBID | --- 29K 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ 8G5 AAWTL ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV ADJBI AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU D-I DIK DU5 DWQXO E3Z EBD EBS EJD EMOBN EOJEC ESX F5P FYUFA GNUQQ GUQSH GX1 HMCUK IAO IEA IHR INH INR IOF IPO ITC KQ8 M1P M2O OBODZ OK1 OVD P2P P6G PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBI RMW RNS SV3 TEORI TR2 TUS UKHRP W3E XSB ~8M AAYXX ABVJJ CITATION H13 IHE IL9 IPNFZ M48 OVT RIG PMFND 3V. 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c469a-af96f1b6931113b31f11ebdd1fe709b60d51f78b0f7506f46c3bf6e101a1588a3 |
| IEDL.DBID | 7X7 |
| ISSN | 0973-1482 1998-4138 |
| IngestDate | Thu Jul 10 22:06:51 EDT 2025 Fri Jul 25 21:06:08 EDT 2025 Tue Jun 17 21:24:31 EDT 2025 Thu Jun 12 23:53:45 EDT 2025 Tue Jun 10 20:33:23 EDT 2025 Thu Apr 24 23:10:07 EDT 2025 Tue Jul 01 01:29:11 EDT 2025 Tue Jun 17 22:48:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Biomarker renal cell carcinoma neutrophil-lymphocyte ratio platelet-lymphocyte ratio inflammation |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-sa/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c469a-af96f1b6931113b31f11ebdd1fe709b60d51f78b0f7506f46c3bf6e101a1588a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2738080546?pq-origsite=%requestingapplication% |
| PQID | 2738080546 |
| PQPubID | 226490 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2739068061 proquest_journals_2738080546 gale_infotracmisc_A727297442 gale_infotracgeneralonefile_A727297442 gale_infotracacademiconefile_A727297442 crossref_citationtrail_10_4103_jcrt_JCRT_482_20 crossref_primary_10_4103_jcrt_JCRT_482_20 wolterskluwer_medknow_10_4103_jcrt_JCRT_482_20_1635_Preopera |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20221001 2022-10-00 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 20221001 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Mumbai |
| PublicationPlace_xml | – name: Mumbai |
| PublicationTitle | Journal of cancer research and therapeutics |
| PublicationYear | 2022 |
| Publisher | Wolters Kluwer India Pvt. Ltd Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd |
| Publisher_xml | – name: Wolters Kluwer India Pvt. Ltd – name: Medknow Publications and Media Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd |
| References | Lee (R17-30-20241021) 2012; 32 Otunctemur (R23-30-20241021) 2016; 42 Byun (R21-30-20241021) 2016; 2016 Finn (R30-30-20241021) 2012; 23 Gu (R25-30-20241021) 2015; 10 Ostroumov (R28-30-20241021) 2018; 75 Templeton (R19-30-20241021) 2014; 106 Gu (R13-30-20241021) 2017; 15 Grivennikov (R6-30-20241021) 2010; 140 Siegel (R1-30-20241021) 2019; 69 Ohno (R16-30-20241021) 2010; 184 Orellana (R27-30-20241021) 2015; 15 Proctor (R12-30-20241021) 2011; 47 Roxburgh (R8-30-20241021) 2010; 6 Dalpiaz (R22-30-20241021) 2014; 110 Rossi (R3-30-20241021) 2018; 36 Dirican (R24-30-20241021) 2013; 18 Wang (R26-30-20241021) 2017; 8 Semeniuk-Wojtaś (R18-30-20241021) 2018; 16 Ferlay (R2-30-20241021) 2019; 144 Sathianathen (R4-30-20241021) 2017; 6 Hutterer (R20-30-20241021) 2014; 32 Ghali (R5-30-20241021) 2019; 2019 Pichler (R9-30-20241021) 2013; 108 Abu-Shawer (R15-30-20241021) 2019; 19 Çalışkan (R31-30-20241021) 2019; 34 de Aquino (R29-30-20241021) 2015; 166 Diakos (R7-30-20241021) 2014; 15 Li (R10-30-20241021) 2014; 134 Chang (R14-30-20241021) 2015; 113 Stojkovic Lalosevic (R11-30-20241021) 2019; 2019 |
| References_xml | – volume: 10 start-page: e0125538 year: 2015 ident: R25-30-20241021 article-title: The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: A systematic review and meta-analysis publication-title: PLoSOne doi: 10.1371/journal.pone.0125538 – volume: 15 start-page: e493 year: 2014 ident: R7-30-20241021 article-title: Cancer-related inflammation and treatment effectiveness publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70263-3 – volume: 2019 start-page: 6036979 year: 2019 ident: R11-30-20241021 article-title: Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer publication-title: Dis Markers doi: 10.1155/2019/6036979 – volume: 47 start-page: 2633 year: 2011 ident: R12-30-20241021 article-title: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.03.028 – volume: 110 start-page: 2531 year: 2014 ident: R22-30-20241021 article-title: Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma publication-title: Br J Cancer doi: 10.1038/bjc.2014.180 – volume: 69 start-page: 7 year: 2019 ident: R1-30-20241021 article-title: Cancer statistics, 2019 publication-title: CA Cancer J Clin doi: 10.3322/caac.21551 – volume: 42 start-page: 678 year: 2016 ident: R23-30-20241021 article-title: Clinical significance of preoperative neutrophil-to-lymphocyte ratio in renal cell carcinoma publication-title: Int Braz J Urol doi: 10.1590/S1677-5538.IBJU.2015.0397 – volume: 15 start-page: 290 year: 2015 ident: R27-30-20241021 article-title: Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells publication-title: BMC Cancer doi: 10.1186/s12885-015-1304-z – volume: 184 start-page: 873 year: 2010 ident: R16-30-20241021 article-title: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma publication-title: J Urol doi: 10.1016/j.juro.2010.05.028 – volume: 166 start-page: 117 year: 2015 ident: R29-30-20241021 article-title: Challenges and future perspectives of T cell immunotherapy in cancer publication-title: Immunol Lett doi: 10.1016/j.imlet.2015.05.018 – volume: 144 start-page: 1941 year: 2019 ident: R2-30-20241021 article-title: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods publication-title: Int J Cancer doi: 10.1002/ijc.31937 – volume: 75 start-page: 689 year: 2018 ident: R28-30-20241021 article-title: CD4 and CD8 T lymphocyte interplay in controlling tumor growth publication-title: Cell Mol Life Sci doi: 10.1007/s00018-017-2686-7 – volume: 6 start-page: 83 year: 2017 ident: R4-30-20241021 article-title: The current status of immunobased therapies for metastatic renal-cell carcinoma publication-title: Immunotargets Ther doi: 10.2147/ITT.S134850 – volume: 113 start-page: 626 year: 2015 ident: R14-30-20241021 article-title: Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma publication-title: Br J Cancer doi: 10.1038/bjc.2015.241 – volume: 106 start-page: dju124 year: 2014 ident: R19-30-20241021 article-title: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dju124 – volume: 2019 start-page: 7309205 year: 2019 ident: R5-30-20241021 article-title: Current status of immunotherapy for localized and locally advanced renal cell carcinoma publication-title: J Oncol doi: 10.1155/2019/7309205 – volume: 23 start-page: viii6 year: 2012 ident: R30-30-20241021 article-title: Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer publication-title: Ann Oncol doi: 10.1093/annonc/mds256 – volume: 32 start-page: 1041 year: 2014 ident: R20-30-20241021 article-title: Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma publication-title: Urol Oncol doi: 10.1016/j.urolonc.2014.04.001 – volume: 16 start-page: e685 year: 2018 ident: R18-30-20241021 article-title: Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and c-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: A systemic review and meta-analysis publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2018.01.010 – volume: 15 start-page: e369 year: 2017 ident: R13-30-20241021 article-title: Pretreatment lymphocyte to monocyte ratio is an independent prognostic factor in metastatic clear cell renal cell carcinoma publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2016.12.001 – volume: 34 start-page: 15 year: 2019 ident: R31-30-20241021 article-title: Elevated neutrophil to lymphocyte and platelet to lymphocyte ratios predict high grade and advanced stage renal cell carcinoma publication-title: Int J Biol Markers doi: 10.1177/1724600818817557 – volume: 2016 start-page: 5634148 year: 2016 ident: R21-30-20241021 article-title: Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in nonmetastatic renal cell carcinoma: A large, multicenter cohort analysis publication-title: Biomed Res Int doi: 10.1155/2016/5634148 – volume: 140 start-page: 883 year: 2010 ident: R6-30-20241021 article-title: Immunity, inflammation, and cancer publication-title: Cell doi: 10.1016/j.cell.2010.01.025 – volume: 6 start-page: 149 year: 2010 ident: R8-30-20241021 article-title: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer publication-title: Future Oncol doi: 10.2217/fon.09.136 – volume: 18 start-page: 413 year: 2013 ident: R24-30-20241021 article-title: The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma publication-title: J BUON – volume: 19 start-page: 1 year: 2019 ident: R15-30-20241021 article-title: Hematologic markers of distant metastases and poor prognosis in gynecological cancers publication-title: BMCCancer – volume: 36 start-page: 1341 year: 2018 ident: R3-30-20241021 article-title: Epidemiology and screening for renal cancer publication-title: World J Urol doi: 10.1007/s00345-018-2286-7 – volume: 32 start-page: 1555 year: 2012 ident: R17-30-20241021 article-title: Pretreatment neutrophil: Lymphocyte ratio as a prognostic factor in cervical carcinoma publication-title: Anticancer Res – volume: 8 start-page: 70874 year: 2017 ident: R26-30-20241021 article-title: Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer publication-title: Oncotarget doi: 10.18632/oncotarget.20147 – volume: 134 start-page: 2403 year: 2014 ident: R10-30-20241021 article-title: Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis publication-title: Int J Cancer doi: 10.1002/ijc.28536 – volume: 108 start-page: 901 year: 2013 ident: R9-30-20241021 article-title: Validation of the pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients publication-title: Br J Cancer doi: 10.1038/bjc.2013.28 |
| SSID | ssj0057228 |
| Score | 2.2951128 |
| Snippet | Background: Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory... Emerging evidences have elucidated the crucial role of inflammation in carcinogenesis and tumor progression. In the recent years, many inflammatory biomarkers... |
| SourceID | proquest gale crossref wolterskluwer |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1635 |
| SubjectTerms | Biological markers Carcinoma, Renal cell Care and treatment Development and progression Evaluation Health aspects Identification and classification Kidney cancer Lymphocytes Medical prognosis Neutrophils Prognosis Statistical analysis |
| SummonAdditionalLinks | – databaseName: Medknow Open Access Journals dbid: W3E link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELemISHQhGCAKAxkJFSEtNA4H05CeKmmTdMkUIU6sTfLdmxg65IoTYXywt_OXT66lq8X3tr60tq-O_uud_c7Ql65gY0y13Ans8CGIJHGiROuHMO5MVIxzlWL9vmRn54HZxfhxQ4Ziv0wq1Ljcqt-K1sHvd_EtrSr__Mq8h1EsEwbkAdwiz0vXWtz2s2Yp51KgsERpmZ4maRyBWZpjVHzPKvgpriScCmkLUQRuP63vMgLMTXss388nOhh5LU9Wte_2oU7A-b6k0td1W_Pjj7NBXwusGv4xvX26yF_l-x9LzAIvrxqc-A3brKT--Reb4LSabfcB2TH5Pvk9oc-yL5PxrMOzro5pPOb6qzlIR3T2Q3QdfOQ_JhVpihNhx1OcyCrivLrt4WzaEBGCt3UhrYCNikXYNKChPw28o5OaVnUmLIEU4K9oqavlIa315g6VFEwq2llcMoYZaAaux8BiXxEzk-O50enTt_PwdHghEtH2oRbpnjiY3975TPLmFFZxqyJ3ERxNwuZjWLlWjBjuA249pXlBg4NycI4lv5jspsXuXlCaAzkNsyyKDIyYNpTVgcgiwz87UzqmI_IZGCD0D3YOfbcWAhwepBxAhknNhg3Im_WT5Qd0Mc_aF8jZwWeAfCtWvalDDA3RNMSU4xug6MWeCMy3qL80mGJ_4nwYIsQlFxvDw9CJHrNWAqsqgKDPwxguS_Xw_gkJs7lpli1NAm2V-FsRN5vCZ-47uot_7pKgZojBkl6-n-PPyN3UEu7NMgDsltXK_MczLlavWh17Sd6fE-O priority: 102 providerName: Wolters Kluwer Health |
| Title | Preoperative neutrophil-lymphocyte ratio/platelet-lymphocyte ratio: A potential and economical marker for renal cell carcinoma |
| URI | http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2022;volume=18;issue=6;spage=1635;epage=1639;aulast=Chandrasekaran;type=0 https://www.proquest.com/docview/2738080546 https://www.proquest.com/docview/2739068061 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ta9RAEF60BVFEtCqe1rKCnAiNl70km0QEOcvVUrAc5Yr3bdlX365JzKXIfRP_gv_QX-JMknuT2i-BZCdhwzO7mcnMPEPIcz90sfEt94wDGMJUWi9JufIs59ZKxThXNdvnCT86C48n0aT94TZr0yoXe2K9UZtc4z_yHpaQgHUThfxt8d3DrlEYXW1baFwn20hdhild8WTpcEVxv-6tiow0HvJdNmHKkPlB76suq1fHB6djAdcFdvte-yz9uznfIrd_5Bi8nn2rc9fXvkCHd8md1nSkgwbre-SazXbIjQ9tcHyHdEcNDfV8n45XVVWzfdqloxVB9fw--TUqbV7YhvObZiBW5sXnL9M_P39P54BurueVpbVq9IopGKOA7SVjr-mAFnmF6UYwLZkZatsqZzg9x7SfkoJJTEuL08YIAdXYuQhE5ANydjgcHxx5bS8GT4MDLT3pUu6Y4mmAvelVwBxjVhnDnI39VHHfRMzFifIdmCDchVwHynELC16yKElk8JBsZXlmHxGagLiLjIljK0Om-8rpEPSIga9spE54h_QWUAjdEpVjv4ypAIcFwRMInlgDr0NeLu8oGpKOK2RfILoC1y88Vcu2DAHmhkxYYoCRaXCywn6HdDckPzU84JcJ7m4IwgLVm8MLRRLtBjETK3XukGfLYbwTk94ym1_UMim2RuGsQ95sKKA4b2ol__uWAszsSCy06fHVM3hCbvaxqKNOUdwlW1V5YZ-CqVWpvXo97ZHtd8OT0SmcvZ8wOH4Mhn8BruAyyQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVOIihKCAMBRYJAiqVBOvL2sbgVAordJbFFWp1LfFXu9yS23jpKryhvgF_oOP4kuY8aVJUOlbH5MdWxvN2dmZzMwZQp5brvYTS3Ez0aAGN4yUGYQ8NhXnSkUx4zwu2T77vHfo7hx5R0vkd9MLg2WVjU0sDXWSSfyPvIMtJODdeC5_l383cWoUZlebERoVLHbV9BRCtvHb7Q-g3xe2vbU53OiZ9VQBU0IoGJmRDrlmMQ8dnLIeO0wzpuIkYVr5VhhzK_GY9oPY0nCZcu1y6cSaK4BuxLwgiBx47xWy7DoQyrTI8vvN_uCgsf2eb5fTXJEDx0SGzSox6jLL6XyVxeTVzsbBUMD3AueLz12E_14HN8jN0wzT5eNvZbX83J23dZvcqp1V2q3QdYcsqXSFXN2v0_ErpD2oiK-n63Q46-Mar9M2Hcwosad3yc9BobJcVSzjNAWxIss_fxn9-fFrNAU8ZXI6UbQEYycfgfsLaDpn7TXt0jybYIETbCtKE6rqvmr4eIyFRgUFJ5wWCreNOQkqcVYSiET3yOGl6Ok-aaVZqh4QGoC49pLE91XkMmnHWrqAXAbReRLJgBuk06hCyJoaHSd0jASESKg8gcoTc8ozyNrZE3lFC3KB7EvUrkCLAW-VUd34AHtD7i3RxVw4hHWubZD2guSninn8PMHVBUEwCXJxuQGSqE3SWMwOkEGenS3jk1hml6rspJQJcRgLZwZ5swBAcVx1Z_73Vwpw7D3RoOnhxTt4Sq71hvt7Ym-7v_uIXLexpaQskFwlrUlxoh6DozeJn9Sni5KPl32g_wKS9G0Z |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preoperative+neutrophil-lymphocyte+ratio%2Fplatelet-lymphocyte+ratio%3A+A+potential+and+economical+marker+for+renal+cell+carcinoma&rft.jtitle=Journal+of+cancer+research+and+therapeutics&rft.au=Chandrasekaran%2C+Deepika&rft.au=Sundaram%2C+Sandhya&rft.au=Maheshkumar%2C+K&rft.au=Kathiresan%2C+N&rft.date=2022-10-01&rft.issn=1998-4138&rft.eissn=1998-4138&rft.volume=18&rft.issue=6&rft.spage=1635&rft_id=info:doi/10.4103%2Fjcrt.JCRT_482_20&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0973-1482&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0973-1482&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0973-1482&client=summon |